Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

66 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

Eligibility Leukemia, B-Cell, Chronic NCT00344825

- 20/09/2021 - 1 Formulaire, 2 Groupes Item, 13 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Vitalis Study - Observational Study on the Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia (B-CLL); ODM derived from: https://clinicaltrials.gov/show/NCT00344825

Eligibility Acute Myeloid Leukemia NCT02034227

- 20/09/2021 - 1 Formulaire, 2 Groupes Item, 21 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia; ODM derived from: http://clinicaltrials.gov/show/NCT02034227

CLL Demographics and Medical History BO17072 NCT00090051 - Demographics and Medical History Chronic Lymphocytic Leukemia NCT00090051

- 15/03/2021 - 1 Formulaire, 8 Groupes Item, 28 Eléments de données, 1 Langue
Groupes Item: Demographics, Serum pregnancy test, History of diseases, History of treatments, Previous treatments chemotherapy, Previous treatments radiotherapy, Surgery, Other treatment
An open-label, multicenter, randomized, comparative, phase III study to evaluate the efficacy and safety of rituximab plus fludarabine and cyclophosphamide (FCR) versus fludarabine and cyclophosphamide alone (FC) in previously treated patients with CD20 positive B-cell chronic lymphocytic leukemia (CLL). NCT00090051 Roche BO17072 FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients

Eligibility B-cell Chronic Lymphocytic Leukemia NCT01217749

- 15/08/2019 - 1 Formulaire, 2 Groupes Item, 32 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL; ODM derived from: https://clinicaltrials.gov/show/NCT01217749

Eligibility Lymphocytic Leukemia, Chronic NCT01283386

- 17/01/2019 - 1 Formulaire, 2 Groupes Item, 10 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Unfavourable Somatic Status; ODM derived from: https://clinicaltrials.gov/show/NCT01283386

Eligibility Richter's Transformation NCT00472849

- 30/08/2017 - 1 Formulaire, 2 Groupes Item, 13 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias; ODM derived from: https://clinicaltrials.gov/show/NCT00472849

Eligibility Leukemia, Lymphocytic, Chronic NCT00464633

- 04/08/2017 - 1 Formulaire, 2 Groupes Item, 14 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL); ODM derived from: https://clinicaltrials.gov/show/NCT00464633

Eligibility Leukemia, Lymphocytic, Chronic NCT00289549

- 21/04/2017 - 1 Formulaire, 2 Groupes Item, 16 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL); ODM derived from: https://clinicaltrials.gov/show/NCT00289549

Eligibility Leukemia NCT00364286

- 18/04/2017 - 1 Formulaire, 2 Groupes Item, 15 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825); ODM derived from: https://clinicaltrials.gov/show/NCT00364286

Eligibility B-Cell Chronic Lymphocytic Leukemia NCT00302861

- 02/04/2017 - 1 Formulaire, 2 Groupes Item, 11 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
A Study to Evaluate the Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL); ODM derived from: https://clinicaltrials.gov/show/NCT00302861

Eligibility Lymphocytic Leukemia, Chronic NCT00532129

- 07/03/2017 - 1 Formulaire, 2 Groupes Item, 9 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia.; ODM derived from: https://clinicaltrials.gov/show/NCT00532129

Eligibility Chronic Lymphocytic Leukemia NCT00438854

- 21/02/2017 - 1 Formulaire, 2 Groupes Item, 16 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Dasatinib in Relapsed Chronic Lymphocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00438854

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial